Keros Therapeutics (KROS) said Wednesday it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to "new observations of pericardial effusion adverse events."
The decision includes all treatment arms, including the 1.5 mg/kg and placebo groups.
Keros Therapeutics halted higher dose treatments of 3.0 mg/kg and 4.5 mg/kg last December due to similar concerns.
Keros Therapeutics shares were down more than 16% in recent premarket activity.
Price: 10.39, Change: -2.09, Percent Change: -16.75
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。